about
Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypesDesign, synthesis and biological evaluation of ligands selective for the melanocortin-3 receptorInvestigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of painA Highly Selective and Potent PTP-MEG2 Inhibitor with Therapeutic Potential for Type 2 DiabetesThe Melanocortin Receptor System: A Target for Multiple Degenerative DiseasesMolecular evolution of a peptide GPCR ligand driven by artificial neural networksGanglioside inhibition of neurite outgrowth requires Nogo receptor function: identification of interaction sites and development of novel antagonistsChemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating ActivityDiscovery and characterization of smORF-encoded bioactive polypeptidesNatural products as sources of new drugs over the 30 years from 1981 to 2010Homology modeling and molecular docking of human pituitary adenylate cyclase‑activating polypeptide I receptor.Constraining cyclic peptides to mimic protein structure motifs.Probing conformational disorder in neurotensin by two-dimensional solid-state NMR and comparison to molecular dynamics simulationsPeptide-based probes for targeted molecular imaging.Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cordLigand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptorsDesign of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challengePeptides and peptide hormones for molecular imaging and disease diagnosisSynthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry.Crossing borders to bind proteins--a new concept in protein recognition based on the conjugation of small organic molecules or short peptides to polypeptides from a designed setPhosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments.A peptide from the beta-strand region of CD2 protein that inhibits cell adhesion and suppresses arthritis in a mouse modelTowards the improved discovery and design of functional peptides: common features of diverse classes permit generalized prediction of bioactivityDesign of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesisBinding of the phage display derived peptide CaIX-P1 on human colorectal carcinoma cells correlates with the expression of carbonic anhydrase IX.Organic chemistry and biology: chemical biology through the eyes of collaboration.Evolution of a potential hormone antagonist following gene splicing during primate evolution.Investigation of the novel lead of melanocortin 1 receptor for pigmentary disorders.Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.Cone snail venomics: from novel biology to novel therapeutics.Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast CancerNew paradigms and tools in drug design for pain and addictionDesign of cyclic and other templates for potent and selective peptide alpha-MSH analogues.Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.A fascinating journey into history: exploration of the world of isonitriles en route to complex amidesApproaches to the rational design of selective melanocortin receptor antagonists.Cancer treatment using peptides: current therapies and future prospectsPnPP-19, a spider toxin peptide, induces peripheral antinociception through opioid and cannabinoid receptors and inhibition of neutral endopeptidaseAn unusual conformation of γ-melanocyte-stimulating hormone analogues leads to a selective human melanocortin 1 receptor antagonist for targeting melanoma cells.Dynamics of ligand binding from 13C NMR relaxation dispersion at natural abundance.
P2860
Q21146715-0E99008E-1A4C-4B84-887B-465EDF7289B5Q24649952-7583DEDA-696F-4F7D-91A1-0DAC31080984Q26863769-A706CC80-A9BF-42E5-9DED-CA19AF2F5CC7Q27674611-C31D5055-2E07-4E83-BDA7-E1B83F4A88E1Q28273671-FB07A89A-FD61-4C4F-8AB7-657F726B6E99Q28729987-70FC961E-DEF8-431D-9F15-7C279E059560Q28771761-FF7D060F-1EF0-4E6C-97B2-572656F1C187Q28822160-7B5283C3-3DE0-47C5-A701-22CCDF543797Q28829292-FDE54159-224A-4EB3-9638-0D69A418738FQ29616640-FC2FA41D-22A2-45AE-9C26-EB006658B0C5Q30365203-8F5BC4F0-ED41-4E78-AE0E-B010F0C7B442Q30367509-FFF7FB3F-1689-4758-81AA-9351AD2DD24BQ30993418-8C3631AB-0FB3-481B-AEE5-F16F3749D8E2Q33526620-E22737AC-707C-489E-BE25-6FCF7A5341C1Q33613843-6F036F4D-E909-4EB6-9159-FC23BA978DF6Q33650270-D2CC0E28-B64B-495F-9E36-04B19CE4240FQ33786376-BB6293E5-9A2C-49A4-90E6-473083941EE3Q33846924-CEA98F76-9BC7-4EE9-B935-3F2990460F6BQ33852418-3CA8DBAC-F21D-49D3-9461-D78C475F6C77Q33861624-986ADF81-8054-44A1-9EFF-A6FBC94E9081Q33975429-7D6CFE26-4EDB-437C-81E7-07AB644C0BE9Q34436433-E0742F2E-2750-462A-9B5B-A26B063AB98EQ34440865-9DFFE698-7437-4182-AA2B-3AEEC902099CQ34478940-25C2692C-7293-41D5-83A2-764280CC7A06Q34497835-07DB7557-281C-4778-B449-B5BB2719CC1AQ34583191-D1BB2626-942F-4B52-A123-574EBF0DF357Q34749669-40FDD6EB-CDF5-4717-A750-4C34B128C5FDQ35137889-776D8740-65FC-4A47-9D95-B31F6FDD39CAQ35185574-9E49CBCA-13D7-4D64-83D4-C49DC8313892Q35432836-D8CF1E93-18FE-43BE-A934-532D1829046FQ35533514-101987DE-A2C7-4AE9-A90D-0063C3D9E71CQ35575224-7AB16976-C75E-4A68-870B-0AD0D9C06DA1Q35676897-462B9348-7571-43FA-BA64-57A9405F5B37Q35783096-AF2C5650-4998-4085-9868-750D6C55BEC0Q36131535-9AE723B6-127A-42E4-9B91-E48A3A59638FQ36170873-33CFD373-16FE-4111-9C4F-07B6E06270DAQ36515785-4BEBD5CA-D3FE-44BA-BE96-E11BB4A7D4CAQ36797368-26A92DFA-F130-42EB-9CD1-E9A35E54747EQ36809168-C0A59F30-5612-448B-9AED-0DA69CC5312FQ37157295-4CDEB4B0-E671-4B4B-A17A-CF255A8FF143
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Designing peptide receptor agonists and antagonists.
@ast
Designing peptide receptor agonists and antagonists.
@en
Designing peptide receptor agonists and antagonists.
@nl
type
label
Designing peptide receptor agonists and antagonists.
@ast
Designing peptide receptor agonists and antagonists.
@en
Designing peptide receptor agonists and antagonists.
@nl
prefLabel
Designing peptide receptor agonists and antagonists.
@ast
Designing peptide receptor agonists and antagonists.
@en
Designing peptide receptor agonists and antagonists.
@nl
P356
P1476
Designing peptide receptor agonists and antagonists.
@en
P2093
Victor J Hruby
P2888
P304
P356
10.1038/NRD939
P577
2002-11-01T00:00:00Z
P6179
1039187806